Introduction
============

Based on colorectal cancer therapy regimen is the surgical removal of solid tumor masses, usually combined with the chemical treatments. However, chemotherapy reaches low efficiency levels with the emergence of resistant tumors and severe side effects [@B1], [@B2]. For this reason, several researches in recent years have been looking to shift the approach as regards designing an alternative treatment. Strategies for targeted therapy have gained immense attention in comparison with the conventional treatment [@B3]. The understanding of apoptosis has enabled the formation of a basis for novel targeted therapeutic approaches capable of targeting signaling pathways that are essential for inducing death in cancer cells [@B4]. This has been shown to be a novel therapeutic approach of inducing apoptosis of cancer cells and should be helpful in developing more effective treatments for colorectal cancer.

Apoptosis has been speculated as the major mechanism for cancer treatment, particularly in chemotherapy-induced cell death, besides being the focus of many preclinical drug investigations [@B5]. Likewise, immunotherapy for cancer requires an apoptosis-sensitive phenotype of target cells, for example, in the case of cetuximab-induced apoptosis through the blocking of the epidermal growth factor receptor (EGFR) [@B6]. Many studies have revealed that extracellular matrix metalloproteinase inducer (EMMPRIN) related with cancer cell apoptosis mediates in a hyaluronan-dependent manner *via* the PI3K and Erk1/2 pathways [@B7]-[@B11]. EMMPRIN, or CD147, is a highly glycosylated cell surface transmembrane glycoprotein that belongs to the Ig superfamily [@B12], [@B13]. Overexpression of this molecule has been noted on the surface of many cancer cells, and it is found to promote multiple properties including cell proliferation, invasiveness, metastasis, angiogenesis, glycolysis, and multi-drug resistance (MDR) [@B10], [@B14]. In 2006,Yang *et al*. reported that the knock-down of EMMPRIN/CD147 expression by RNA interference (RNAi) sensitized cancer cells to anoikis, as demonstrated by caspase-3 activation, increased DNA fragmentation, and decreased cellular viability in human breast cancer cells [@B15]. Compared to other similar technologies aimed at the ablation of protein function, such as intracellular antibody or intrabody, this technology knockout is at the post-translational level. It has more specific subcellular compartments due to the addition of localization signal sequences as well as precise epitopes on the target proteins [@B16].

Several studies have demonstrated the potential of intrabodies in therapeutic applications. The first promising intrabody approaches in cancer treatment which have been published in immunotherapy involve the application of single-chain variable fragment (scFv) against human epidermal growth factor receptor 2 (HER2) in breast cancer [@B17]. Until now, scFv intrabody has been proven to be promising in several types of cancer [@B18]-[@B22]. Recently, our group generated the functional intrabody against EMMPRIN (scFv-M6-1B9) and transferred the gene encoding scFv-M6-1B9 intrabody *via* adenovirus serotype 5 vector (Ad5-*scFv-M6-1B9*) which retained EMMPRIN in ER with the KDEL peptide (ER retention signal) [@B23].

Gene transfer systems are basically classified into non-viral and viral transfer systems. At present, the main disadvantage of non-viral vector is the low transduction efficiency and transient transgene expression, no specific cell targeting and difficult *in vivo* applications [@B24]. The retroviral vectors are suitable for *ex vivo* gene therapy, and despite the disadvantages, retroviral gene delivery systems have been used already in a number of clinical trials [@B24], [@B25]. However, integration of retrovirus genomes into the host genome might induce mutagenesis in some clinical applications [@B26]. Adenoviruses (Ad) have been adopted as potential delivery vehicles in vector system for cancer gene therapy [@B27]. They rapidly infect a broad range of human cells as well as tend to yield high levels of gene transfer compared to the levels achieved with other currently available vectors. Rein *et al*. achieved higher clinical efficacy of adenoviral vector-mediated strategies in cervical cancer gene therapy [@B28]. Furthermore, Ad vectors bearing chimeric fiber (Ad5/F35), Ad5 fiber tail domain and Ad35 fiber shaft and knob, were developed and found to have high transduction efficiencies [@B29]. Since CD46 is a receptor for Ad5/F35 which is highly expressed in most cancer cells, chimeric adenovirus 5/F35 (Ad5/F35) was observed to have high potency for transduction in various human cancer cell lines [@B30].

In our study, we demonstrated earlier that chimeric adenovirus 5/F35 carrying gene encoding scFv against EMMPRIN (Ad5/F35-*scFv-M6-1B9*) is effective in diminishing EMMPRIN cell surface expression and subsequently decreasing cancer cell proliferation, invasion, and metastasis in the colorectal cancer cell line, Caco-2 [@B31]. However, the apoptotic effect of reducing EMMPRIN cell surface levels using intrabody technique in established colorectal cancer cells has hitherto been unclear. Therefore, the aim of the present study was to investigate the molecular mechanism by which EMMPRIN cell surface down-regulation*via* scFv-M6-1B9 intrabody induces apoptosis in the colorectal cancer cell line, Caco-2. Moreover, carcinoembryonic antigen (CEA) monitoring to predict the response toward down-regulating the EMMPRIN molecule was investigated. These findings might provide a new strategy that would lead to the development of targeted-therapy and its role in the management of colorectal cancer.

Materials and Methods
=====================

Cell culture
------------

Human colorectal cancer cell line Caco-2 (kindly obtained from Assoc. Prof. Dr. Samlee Mankhetkorn, Laboratory of Physical Chemistry, Molecular and Cellular Biology, Department of Radiologic Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand) was cultured in Dulbecco\'s Modified Eagle\'s medium (DMEM) (Invitrogen, Green Island, NY) supplemented with 10% fetal bovine serum (FBS), penicillin (100 Units/mL), and streptomycin (100 µg/mL), and incubated in a humidified atmosphere with 5% CO~2~ at 37°C.

Chimeric adenoviruses
---------------------

The chimeric adenovirus 5/F35 harboring *scFv-M6-1B9* gene which encoding intrabody specific to EMMPRIN (Ad5/F35-*scFv-M6-1B9*) and the adenovirus harboring scFv irrelevant intrabody (Ad5/F35-*scFv-irrelevant*), both carrying the green fluorescent protein (GFP) reporter gene, were generated as described in another research review [@B31].

EMMPRIN expression
------------------

The EMMPRIN expression of the Caco-2 cell was analyzed using western blotting analysis. In brief, untransduced, Ad5/F35-*scFv-irrelevant*, or Ad5/F35-*scFv-M6-1B9* transduced cell lysates were prepared in the compartments of the membrane and cytosol by using FractionPREP™ Cell Fractionation Kit (BioVision, Milpitas, CA) by following the instructions of the manufacturer and supplemented with protease inhibitor cocktail set I (Calbiochem, Darmstadt, Germany). The protein concentration of each fraction was quantified using a BCA protein assay kit (Merck, Darmstadt, Germany). Equal amounts of protein samples (40 µg) were separated on 15% sodium dodecyl sulphate (SDS)-polyacrylamide gels and transblotted onto polyvinylidene difluoride (PVDF) membranes (Merck, Darmstadt, Germany). For immunoblotting detection, the membranes were incubated overnight with 1 µg/mL of rabbit anti-EMMPRIN pAb (Invitrogen, Burlington, Canada). The antibodies were diluted in a blocking buffer composed of 5% skim milk in phosphate buffered saline (PBS). Blots were subsequently incubated for 1 h with peroxidase-conjugated goat anti-rabbit-IgG pAb (KPL, Madison, WI). After the washing step, the reactions were visualized using luminata forte western HRP substrate (Millipore, Billerica, MA) and exposed to Hyperfilm™ ECL (Thermo Scientific, Rockford, IL). The band density was measured using the ImageQuant TL software (GE Healthcare, Piscataway, NJ).

Apoptosis induction
-------------------

Caco-2 cells (1×10^5^/well) transduced with 100 MOI of Ad5/F35-*scFv-irrelevant* or Ad5/F35-*scFv-M6-1B9*. After 48 h of transduction, the cells were harvested and washed twice with cold PBS. The supernatant was discarded and the cells were resuspended with 300 µL of cold PBS, followed by fixation of the cells with 700 μL absolute ethanol and incubation on ice for 30 min. Then, the cells were washed twice and 1 mL of propidium iodide (PI) solution (20 μg/mL PI, 0.1% TritonX-100, 2 mM EDTA, and 8 μg/mL RNase) was added. Finally, the cells were analyzed using FACSort flow cytometer and cell quest software (Becton Dickinson, Franklin Lakes, NJ).

Phosphatidylserine externalization
----------------------------------

The externalization of phosphatidylserine was measured using a FACSort flow cytometer by following the instructions provided with the Annexin V-PE apoptosis detection kit (Calbiochem, Darmstadt, Germany). In brief, after transducing the Caco-2 cells with Ad5/F35-*scFv-irrelevant* or Ad5/F35-*scFv-M6-1B9* at MOI of 100 for 48 h, the cells were harvested, washed twice with cold PBS, and resuspended in 500 µL of binding buffer. Then, the cells were stained with 5 µL of PE-conjugated Annexin V/PI and incubated at room temperature for 5 min in the dark. Finally, the cells were analyzed by flow cytometry.

DNA fragmentation
-----------------

DNA fragmentation was carried out using the *In Situ* Cell Death Detection Kit, TMR red (Roche, Mannheim, Germany), according to the instructions provided by the manufacturer. Briefly, after 48 h of transduction with 100 MOI of Ad5/F35-*scFv-irrelevant* or Ad5/F35-*scFv-M6-1B9*, the cells were fixed with the fixative solution (4% Paraformaldehyde in PBS pH 7.4) for 1 h at room temperature. The cells were washed twice and incubated with the permeabilization solution (0.1% Triton X-100 in 0.1% Sodium citrate) for 2 min on ice. After the permeabilization, the cells were washed twice and incubated with 50 µL of TUNEL reaction mixture (label solution and enzyme solution) for 1 h, at 37°C, in the dark. The cells were then washed twice and analyzed by confocal laser scanning microscopy (CLSM) (Nikon Instruments, Melville, NY) and flow cytometry.

Expression of mRNAs of apoptosis-related genes
----------------------------------------------

The effects of EMMPRIN down-regulation*via* scFv-M6-1B9 intrabody on apoptosis-related gene expression were determined by quantitative real-time RT-PCR assay. The total RNA from Caco-2 cells transduced for 48 h was extracted using Total RNA Isolation NucleoSpin^®^ RNA II (Clontech, Mountain View, CA), according to the instructions provided by the manufacturer. Complementary DNA (cDNA) were obtained by reverse transcription (RT) of 0.7 µg total RNA, using oligo(dT)~18~ primers in the RevertAid^TM^ First Strand cDNA Synthesis (Thermo Scientific, Rockford, IL) by following the enzyme supplier\'s instructions.

Real-time RT-PCR assays for the quantitative determination of the mRNAs were performed using the MiniOpticon™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA). The amplifications were performed in 25 µL mixtures containing 2.5 µL cDNA preparation and 2×SYBR Green qPCR Master Mix (Thermo Scientific, Rockford, IL), according to the instructions provided by the manufacturer. The primer sets for Bcl-2, cytochrome *c,*and caspase-3 are listed in Table [1](#T1){ref-type="table"}. The PCR reactions were amplified with initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 sec, annealing at 56°C for 30 sec, and extension at 60°C for 1 min. After the final cycle, the reaction was held in the final extension step at 60°C for 5 min. Melting curve analysis was performed to ensure that the specific desired amplicon was detected. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. The normalized mRNA expression was analyzed using the comparative C~T~ method [@B32].

Expression of apoptosis-related proteins
----------------------------------------

The effects of EMMPRIN down-regulation*via* scFv-M6-1B9 intrabody on the expression of apoptosis-related proteins were determined using western blotting analysis. Untransduced, Ad5/F35-*scFv-irrelevant*, or Ad5/F35-*scFv-M6-1B9* transduced cell lysates were prepared using RIPA buffer supplemented with a mixture of protease inhibitors (Merck, Darmstadt, Germany). To determine the translocation of cytochrome *c* from mitochondria to the cytosol, the compartments were separated using the Mitochondria/Cytosol Fractionation Kit (BioVision, Milpitas, CA), according to the instructions provided by the manufacturer. Immunodetection was carried out with rabbit anti-Bcl-2 mAb (1:1000) \[mouse anti-cytochrome *c* mAb (1:500) or mouse anti-caspase-3 mAb (1:500)\] in 5% skim milk in PBS (all the antibodies were purchased from Merck, Darmstadt, Germany). This step was followed by incubation with peroxidase-conjugated goat anti-rabbit-IgG pAb (KPL, Madison, WI) or anti-mouse-IgG pAb (Merck, Darmstadt, Germany).The reactions were visualized using luminata forte western HRP substrate and the mixture was immediately exposed to Hyperfilm™ ECL.

Carcinoembryonic antigen (CEA) level
------------------------------------

### CEA secretion

The CEA secretion level was examined using the automated ADVIA Centaur^®^ CEA assay system (Siemens Diagnostics, Deerfield, IL) based on the two-site sandwich immunoassay which uses direct chemiluminometric technology. The Caco-2 cells (1×10^4^per well) were plated on a 24-well tissue culture plate and transduced with 100 MOI of Ad5/F35-*scFv-irrelevant* or Ad5/F35-*scFv-M6-1B9* at 5% CO~2~, at 37°C. The cultured medium was changed at a regular time interval of 2 days with half volume. After 7 days and 10 days of incubation, the supernatant was collected and the CEA concentration was evaluated using the automated analyzer [@B33].

### *CEA* mRNA expression

The effect of EMMPRIN down-regulation on the *CEA* mRNA level was also determined by quantitative real-time RT-PCR assay, as described previously. RT-PCR was performed using the CEA primer set [@B34] and listed in Table [1](#T1){ref-type="table"}. GAPDH was performed as the internal control. The normalized mRNA expression was determined using the comparative C~T~ method.

Statistical analysis
--------------------

The results were presented as the *mean ± s.e.m.* of the three independent experiments. The comparison between the groups was carried out by one-way ANOVA using the SPSS Statistics 17.0 software and statistical significance was set at 95% (*p*\<0.05).

Results
=======

Accumulation of EMMPRIN inside cell mediated scFv-M6-1B9 intrabody
------------------------------------------------------------------

Our previous study revealed for the first time that scFv-M6-1B9 intrabody has the ability to down-regulate EMMPRIN cell surface expression on colorectal cancer cell, Caco-2,*via*flow cytometry [@B31]. To confirm the reduction of the EMMPRIN cell surface expression due to its accumulation inside the cells, immunoblotting was performed. The reduction of EMMPRIN cell surface expression had been demonstrated in the membrane fraction protein of the Caco-2 cells expressing scFv-M6-1B9 intrabody by 50%, compared to untransduced and irrelevant control. Interestingly, increasing accumulation of EMMPRIN was found in the cytoplasmic fraction protein of the Caco-2 cells expressing scFv-M6-1B9 intrabody, as shown in Figure [1](#F1){ref-type="fig"}. This indicates that the scFv-M6-1B9 intrabody dramatically reduced EMMPRIN cell surface expression and that these molecules accumulated inside the Caco-2 cells.

Induction of Caco-2 cell apoptosis by EMMPRIN down-regulation mediated scFv-M6-1B9 intrabody
--------------------------------------------------------------------------------------------

To determine whether EMMPRIN down-regulation *via* scFv-M6-1B9 intrabody could influence apoptosis, apoptotic induction in Caco-2 cells transduced with Ad5/F35-*scFv-irrelevant* and Ad5/F35-*scFv-M6-1B9* was analyzed using flow cytometry. Transduced GFP-positive cells were gated for further analysis of PI staining. Apoptotic cells with DNA content being lessthan the G1-phase cells, coupled with the reduced DNA content of the apoptotic nuclei, resulted in the hypodiploid DNA peak observed in the DNA fluorescence histogram. The percentage of apoptosis in the Caco-2 cells expressing scFv-M6-1B9 intrabody (43.6%) was observed to be significantly higher than the percentage in the scFv-irrelevant control (4.2%), as shown in Figure [2](#F2){ref-type="fig"}A.

To confirm whether phosphatidylserine externalization had any effect during the development of apoptosis, Annexin V assay was performed. After 48 h of incubation, transduced GFP positive cells were gated and further analyzed to determine the percentage of PE conjugated Annexin V/PI-positive cells. Caco-2 cells expressing scFv-M6-1B9 intrabody were observed to have increased Annexin V-positive cells (39.1%) (Annexin V+/PI- and Annexin V+/PI+) compared with the irrelevant control (7.0%) as presented in Figure [2](#F2){ref-type="fig"}B.

TUNEL assay was performed for detecting DNA fragmentation, a characteristic hallmark of apoptosis, by confocal laser scanning microscopy (CLSM) and flow cytometry. DNA fragmentation was observed to be superior in Caco-2 cells expressing scFv-M6-1B9 intrabody than in irrelevant scFv intrabody (Figure [2](#F2){ref-type="fig"}C). To quantify the DNA fragmentation in the Caco-2 cells, transduced GFP positive cells were gated and the TUNEL-positive cells were further analyzed using flow cytometry. As illustrated in Figure [2](#F2){ref-type="fig"}D, the percentage of TUNEL-positive cells in the Caco-2 cells expressing scFv-M6-1B9 intrabody was observed to undergo a significant increase of 13.19%. As with TUNEL staining, there were no differences between the cells expressing irrelevant scFv intrabody and the untransduced cells. The result demonstrates that Caco-2 cells expressing scFv-M6-1B9 intrabody exhibit an increment in DNA fragmentation compared to irrelevant control.

Activation of mitochondrial apoptosis signaling in Caco-2 cells expressing scFv-M6-1B9 intrabody
------------------------------------------------------------------------------------------------

To further examine the possible apoptosis mechanism involved in the EMMPRIN down-regulation of Caco-2 cells, quantitative real-time RT-PCR was utilized to analyze the mRNA expressions of *Bcl-2, cytochrome c,* and *caspase-3*. The results revealed that *caspase-3* mRNA expression had markedly increased in the Caco-2 cells expressing scFv-M6-1B9 intrabody compared with the irrelevant control cells (p\<0.05), as shown in Figure [3](#F3){ref-type="fig"}A. We found no appreciable alterations in the *Bcl-2* and *cytochrome c* mRNA expression levels in the Caco-2 cells expressing scFv-M6-1B9 intrabody and the irrelevant control.

We then investigated the effect of this protein expression mediated EMMPRIN down-regulation in Caco-2 cells *via* scFv-M6-1B9 intrabody. The western immunoblotting technique was used to detect the expression of Bcl-2, cytochrome *c*, and caspase-3. The expression of GAPDH was used as the internal control to reveal equal loading of protein samples. Our data showed that the down-regulation of EMMPRIN reduced the expression of the Bcl-2 protein and the translocation of cytochrome *c*from mitochondria into cytosol. Moreover, the cleaved caspase-3 protein was most remarkable in the Caco-2 cells expressing scFv-M6-1B9 intrabody. Contrarily, all the proteins were not found altered in untransduced and irrelevant control cells. Thus, these results indicate that EMMPRIN down-regulation by scFv-M6-1B9 intrabody has the ability to activate Caco-2 cells apoptosis *via* mitochondrial pathway.

Monitoring of CEA expression level
----------------------------------

The objective was to examine the effect of EMMPRIN down-regulation by scFv-M6-1B9 intrabody on CEA release from Caco-2 cells. CEA secretion was examined by measuring the CEA concentration in the Caco-2 cell culture supernatant. Noteworthily, more than 50% inhibition of the CEA release was produced in the Caco-2 cells expressing scFv-M6-1B9 intrabody after 10 days of incubation, as demonstrated in Figure [4](#F4){ref-type="fig"}A. Contrary to this observation, the untransduced and irrelevant control cells both showed high CEA levels in the supernatant.

To further determine the effect of EMMPRIN down-regulation by scFv-M6-1B9 intrabody on *CEA* mRNA expression in Caco-2 cells, real-time RT-PCR was performed. The results revealed the *CEA* mRNA expression after 7 days and 10 days of incubation of the Caco-2 cells. Significant reduction in the *CEA* mRNA expression was detected in the Caco-2 cells expressing scFv-M6-1B9 intrabody at day 10 compared with the irrelevant control cells, as illustrated in Figure [4](#F4){ref-type="fig"}B (*p*\<0.05). Thus, this result suggests that the down-regulation of EMMPRIN by the scFv-M6-1B9 intrabody significantly decreased CEA in both secreted and mRNA expression levels.

Discussion
==========

EMMPRIN has been extensively studied and well established as playing a role in cancer progression [@B35]. Moreover, it has been characterized as a mediator of anti-apoptotic function and chemoresistance [@B36]. It has been reported that EMMPRIN can effectively protect apoptosis in oral squamous carcinoma cells and melanoma cell line A375 [@B37]. In addition, silencing EMMPRIN/CD147 mediated RNAi has been found to reduce X-chromosome linked inhibitor of apoptosis protein (XIAP) expression and increase chemosensitivity to 5-fluorouracil (5-FU) in human oral squamous carcinoma cells [@B38]. Therefore, the relevance of EMMPRIN as a target to induce apoptosis is shown to be significant as a valuable therapeutic in the case of cancers including colorectal cancer. These induce apoptosis directly, thus providing less opportunity for gained drug resistance, reduced mutagenesis, and toxicity [@B39].

In current study, we focused on functional activity of scFv-M6-1B9 intrabody counteract *in situ* EMMPRIN expression in Caco-2 cells. Cytoplasmic accumulation of the EMMPRIN molecule and significant decrease in the cell surface expression were found in *scFv-M6-1B9* intrabody transduced Caco-2 cells. Hence, the particular advantage of the ER-targeted intrabody technology provides a simple and effective means of inhibiting the transport of integral membrane proteins to the cell surface. Based on the increasing number of *in vitro* and *in vivo* applications of ER-targeted intrabody, including in cancer [@B19], [@B40], infectious diseases [@B41], and autoimmune diseases [@B42], it is worth assessing its potential therapeutic efficacy.

This functional intrabody effects significant reduction in the EMMPRIN cell surface expression and perturbation as regards the proliferation property of the colorectal cancer cell, Caco-2. Furthermore, intracellular accumulation of MCT1 results in the increasing of intracellular lactate levels as a consequent effect of EMMPRIN down-regulation by scFv-M6-1B9 intrabody in Caco-2 cells [@B31]. We hypothesized that the disturbance of this molecule by decreased cell proliferation and intracellular accumulation of lactate might promote programmed cell death response in Caco-2 cells. Several studies have reported that the down-regulation of EMMPRIN/CD147 using siRNA technique increased apoptosis in head and neck squamous cell carcinoma (HNSCC) cell lines [@B43] and human umbilical vein endothelial cells (HUVECs) [@B9]. Our first observation is that down-regulation of EMMPRIN *via* scFv-M6-1B9 intrabody showed an increase in apoptotic cells, which was revealed by PI staining. This observation is based on the notion of PI, which is capable of binding DNA, which makes it probable to label fragmented DNA content of apoptotic cells [@B44]. During the progression of apoptosis, cells frequently exhibited phosphatidylserine in the outer layers of the plasma membrane, which has been translocated from the inner leaflet of plasma membrane [@B45]. Notably, this demonstrates the alteration of both early and late apoptotic cells, thus clearly indicating that Caco-2 cells expressing scFv-M6-1B9 intrabody had already started the apoptotic process with increased plasma membrane permeability to PI dye and Annexin V. The more pronounced effect of EMMPRIN down-regulation on apoptosis induction, measured by TUNEL assay, is presented in the DNA fragmented response, a morphological hallmark of apoptosis in the nucleus. In this study, we observed substantial increment of DNA fragmentation in the Caco-2 cells expressing scFv-M6-1B9 intrabody. These results are indicative of DNA damage, which could be one of the reasons for increased apoptotic cells and induced apoptosis processes observed in the down-regulation of EMMPRIN by the scFv-M6-1B9 intrabody.

The possible signaling of the molecules and the mechanisms involved in the apoptosis triggered by EMMPRIN down-regulation*via* scFv-M6-1B9 intrabody was also investigated. The particular importance of the effect of the intrabody against EMMPRIN is in its specific function inside the cell. We, therefore, focused on the mitochondrial (intrinsic) pathway in the EMMPRIN down-regulation induced apoptosis. It is well recognized that the mitochondrial pathway of apoptosis is regulated by the Bcl-2 family of proteins consisting of pro-apoptotic and anti-apoptotic proteins [@B46]. Bcl-2, an anti-apoptotic protein, is the central regulator of the mitochondrial outer membrane permeability and promotes the release of the cytochrome *c*[@B47]. In general, cytochrome *c* is located in the mitochondrial intermembranous space and released into the cytosol when mitochondrial apoptosis is activated. It finally activates downstream caspase-3 to initiate apoptosis [@B48]. Our finding that Caco-2 cells expressing scFv-M6-1B9 intrabody demonstrate the reduction of Bcl-2 also provides evidence for the accumulation of cytochrome *c* in the cytosolic compartment. In addition, the caspase-3 was found to significantly increase in both mRNA and protein expression levels. This observation suggests that the main mechanism of apoptosis response is through EMMPRIN down-regulation mediated scFv-M6-1B9 intrabody induction. The key function of this mechanism is the decrease in the level of the anti-apoptotic protein as a result of mitochondrial outer membrane permeabilization. This is followed by promotion of the cytochrome *c* release from the mitochondria, which ultimately leads to downstream cleavage of executor caspase-3. These observations support our hypothesis that these molecules in the mitochondrial pathway are involved in the regulation of Caco-2 cell apoptotic regulation by way of EMMPRIN down-regulation.

Carcinoembryonic antigen (CEA) is the most widely used tumor marker worldwide, especially in colorectal cancer [@B49]. Recently, Peng*et al*. revealed through evaluation that the combination of CEA and Ki67 protein as a prognostic marker for colorectal cancer has better prognostic value than CEA by its own [@B50]. There have been reports that EMMPRIN cell surface expression also correlates with clinical prognosis of various human malignancies including breast cancer [@B51], pulmonary adenocarcinoma [@B52], and colorectal cancer [@B53], [@B54]. Interestingly, Caco-2 cells expressing scFv-M6-1B9 intrabody was observed to demonstrate statistically significant decrease in CEA expression at protein and mRNA levels. This reduction might have been caused by cell death or by the interference of secretory pathway in the down-regulation of EMMPRIN *via* the scFv-M6-1B9 intrabody. However, little is currently known about the underlying molecular mechanism. These results provide further insight into the role of EMMPRIN in CEA secretory pathway and its interaction. Moreover, developing these combinations might be used as prognostic markers in colorectal cancer.

It has been well established that EMMPRIN acts as a chaperone for monocarboxylate transporter 1 (MCT1) which is an accompaniment during the maturation in the ER and the translocation to the plasma membrane [@B55]. These interactions play an important role in lactate transport responsible for cellular pH regulation in relation to proliferation, transformation, and apoptosis [@B56]-[@B59]. The elevation of lactate and the further decrease in the intracellular pH (pH~i~) are caused by the changes in the H^+^/lactate co-transporters which possess the ability to protect the cells from apoptosis by maintaining pH~i~[@B60]. It is convincingly evident that acidic pH~i~triggers the apoptosis hallmarks such as nuclear condensation, cytoplasmic vacuolization, and endonucleosome DNA degradation [@B61]. Our current study demonstrates that EMMPRIN and MCT1 translocation were defective in the Caco-2 cells expressing the scFv-M6-1B9 intrabody. These cells effectively restrain the clearance of intracellular lactate and, ultimately, acidosis facilitates the occurrence of apoptosis. The possible mechanism of the acidic pH~i~ potentially playing important roles in activating apoptosis is shown in three pathways: (i) by shifting the mitochondrial membrane potential (Δψm) directly or promoting the binding of Bcl-2 to the Bcl-2 19 kDa interacting protein (BNIP3), which leads to increased mitochondrial membrane permeability [@B62]; (ii) by activating nuclear localized endonucleases involved in DNA fragmentation [@B63]; and (iii) by activating caspase-3, a pro-apoptotic protease that, in turn, inactivates proteins vital for normal cellular function [@B64]. Thus, the down-regulation of EMMPRIN by scFv-M6-1B9 intrabody induces apoptosis cell death in the colorectal cancer cell, Caco-2, and this is clearly associated with an elevated intracellular acidosis and eventually the consequence of the activation of apoptosis signaling molecules, as presented in Figure [5](#F5){ref-type="fig"}.

In summary, the effective scFv-M6-1B9 intrabody is of paramount importance for down-regulating EMMPRIN cell surface expression on Caco-2 cells. Furthermore, this biologically active protein can potentially induce Caco-2 cell apoptosis with down-regulation of Bcl-2 *via* mitochondrial pathway stimulation. This is the first time that evidence of the association between EMMPRIN and CEA expression in colorectal cancer cells has been established. This could be considered to be supporting the notion of novel molecule involved in combined markers in the monitoring of colorectal cancer treatment. Thus, EMMPRIN down-regulation by scFv-M6-1B9 intrabody is evidently an attractive concept for targeted colorectal cancer gene therapy and colorectal cancer management.
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![**Down-regulation of EMMPRIN cell surface expression *via* scFv-M6-1B9 intrabody and its accumulation inside Caco-2 cells.** (A) Western blotting analysis of EMMPRIN protein expression and (B) densitometry analysis of EMMPRIN expression. The white, gray, and black bars represent the protein fractions from untransduced, Ad5/F35-*scFv-irrelevant*, and Ad5/F35-*scFv-M6-1B9* transduced Caco-2 cells, respectively. Y-axis is the fold change of the EMMPRIN expression which was normalized with GAPDH. \* *p*\<0.05, as determined by one-way ANOVA.](jcav06p0276g001){#F1}

![**EMMPRIN down-regulation induced apoptosis in Caco-2 cells.**Caco-2 cells were transduced with Ad5/F35-*scFv-irrelevant* or Ad5/F35-*scFv-M6-1B9*. Transduced GFP positive cells were used for the apoptosis studies. (A) FACS analysis with PI staining for the detection of apoptotic cells. The histogram presents the percentage of apoptotic cells in sub-G1 peak, which was calculated as the percentage of all the transduced cells. (B) Detection of phosphatidylserine externalization by Annexin V assay. The dual parametric dot plot shows the viable cell population in the bottom left quadrant (Annexin V^-^ PI^-^), the early apoptotic cells in the bottom right quadrant (Annexin V^+^ PI^-^), the late apoptotic cells in the top right quadrant (Annexin V^+^ PI^+^), and the necrotic cells in the top left quadrant (Annexin V^-^ PI^+^). Identification of DNA fragmentation by TUNEL assay, using (C) CLSM and (D) FACS analysis. Representative fluorescent images of TUNEL showed DAPI (blue) stained nuclei, transduced cells (green), and TUNEL-positive cells (red). \**p*\<0.05, as determined by one-way ANOVA.](jcav06p0276g002){#F2}

![**Activation of mitochondrial apoptosis signaling in EMMPRIN down-regulated Caco-2 cells.**(A) Detection of *Bcl-2, cytochrome c,*and *caspase-3* mRNA expression levels. Transduced Caco-2 cells were extracted for total RNA and reverse transcribed into cDNA. The expression of *Bcl-2*, *cytochrome c,*and *caspase-3* mRNAs were analyzed using real-time RT-PCR analysis. *GAPDH* mRNA was used as the internal control. The normalized mRNA expression was analyzed using the comparative C~T~ method. The white and black bars represent Ad5/F35-*scFv-irrelevant* and Ad5/F35-*scFv-M6-1B9* transduced Caco-2 cells, respectively. The data are presented as mean±s.e.m. \**p*\<0.05, as determined by one-way ANOVA. (B) The expression levels of Bcl-2, cytochrome *c*, and caspase-3 were determined by western blotting. The immunoblots were detected using rabbit anti-Bcl-2 mAb (or mouse anti-cytochrome *c*mAb, and mouse anti-caspase-3 mAb), followed by peroxidase-conjugated goat anti-rabbit IgG pAb (or anti-mouse IgG pAb). GAPDH was used as the internal control.](jcav06p0276g003){#F3}

![**EMMPRIN down-regulation by scFv-M6-1B9 intrabody affecting decline of CEA level.** Caco-2 cells transduced for 7 days and 10 days were collected as the supernatant, extracted cells for total RNA, and reverse transcribed into cDNA. (A) CEA secretions in the Caco-2 cell supernatant. The amount of CEA released into the medium was determined using an automated analyzer. (B) The expression of *CEA* mRNA was analyzed using real-time RT-PCR. *GAPDH* mRNA was used as the internal control. The normalized mRNA expression was analyzed using the comparative C~T~ method. The white and black bars represent day 7 and day 10 of incubation, respectively. The data are presented as mean±s.e.m. \**p*\<0.05, as determined by one-way ANOVA.](jcav06p0276g004){#F4}

###### 

**Schematic diagram of possible apoptotic mechanism underlying EMMPRIN down-regulation *via* scFv-M6-1B9 intrabody.**(A) EMMPRIN facilitates proper expression of MCT1 at the cell surface. This association plays an important functional role in lactate transport. In cancer cells, an excess of lactic acid is produced by aerobic glycolysis, which must be rapidly exported across the plasma membrane to avoid a drop in pH~i~ [@B57], [@B65]. (B) The scFv-M6-1B9 intrabody can specifically trap the EMMPRIN molecule within the ER, based on the ER retention signal. Suppression of EMMPRIN-MCT1 complex by the down-regulation of EMMPRIN, which resulted in the inhibition of the lactate transporter. (C) Blocking of lactate transport leads to the accumulation of intracellular lactate inside the cell [@B31]. The acidic pH~i~ can be stimulated by different pathways, which are as follows: (i) by altering the mitochondrial membrane potential (Δψm) directly or by increasing the permeability of the outer mitochondrial membrane by promoting the binding of Bcl-2 [@B62]; (ii) by activating nuclear localized endonucleases, a key enzyme that mediates regulated DNA fragmentation and chromatin condensation in response to apoptotic signals [@B63]; and (iii) by activating caspase-3, a pro-apoptotic cysteine protease involved in the activation cascade of caspases responsible for apoptosis execution [@B64].
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###### 

List and sequence of primers

  --------------------------------------------------------------------
  Primers                Sequences                        References
  ---------------------- -------------------------------- ------------
  Bcl-2_Fwd\             5-TCGCCCTGTGGATGACTG-3\          [@B66]
  Bcl-2_Rev              5-CAGGAGAAATCAAACAGAGGC-3        

  Cytochrome *c*\_Fwd\   5-GAGCGGGAGTGTTCGTTGT-3\         [@B66]
  Cytochrome *c*\_Rev    5-GTCTGCCCTTTCTTCCTTCT-3         

  Caspase-3_Fwd\         5\'-TCACAGCAAAAGGAGCAGTTT-3\'\   [@B67]
  Caspase-3_Rev          5\'-CGTCAAAGGAAAAGGACTCAA-3\'    

  CEA_Fwd\               5\'-CCATGGAGTCTCCCTCG-3\'\       [@B34]
  CEA_Rev                5\'-GTAGCTTGCTGTGTCATTTC-3\'     

  GAPDH_Fwd\             5\'-GAAGGTGAAGGTCGGAGTC-3\'\     [@B68]
  GAPDH_Rev              5\'-GAAGATGGTGATGGGATTTC-3\'     
  --------------------------------------------------------------------

[^1]: Competing Interests: The authors have declared that no competing interest exists.
